Pacira Biosciences (NASDAQ: PCRX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Pacira Biosciences reported 16 open-market sales of 101,688 shares ($2.5m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 30 October 2026 | Cross Shawn | Chief Financial Officer | Shares withheld for tax | −9,540 | $36.39 | 95,801 | Form 4 |
| 8 October 2026 | Riker Lauren | Senior Vice President, Finance | Option exercise, 10b5-1 plan | +6,000 | $32.35 | 68,284 | Form 4 |
| 8 October 2026 | Riker Lauren | Senior Vice President, Finance | Open-market sale, 10b5-1 plan | −6,000 | $36.32 | 62,284 | Form 4 |
| 17 August 2026 | Slonin Jonathan | Chief Medical Officer | Open-market sale, 10b5-1 plan | −3,040 | $23.23 | 216,384 | Form 4 |
| 11 June 2026 | Riker Lauren | Senior Vice President, Finance | Open-market sale, 10b5-1 plan | −6,115 | $23.50 | 62,284 | Form 4 |
| 10 June 2026 | Brege Laura | Director | Grant or award | +6,405 | — | 30,120 | Form 4 |
| 10 June 2026 | Froimson Mark | Director | Grant or award | +6,405 | — | 26,541 | Form 4 |
| 10 June 2026 | Bigal Marcelo | Director | Grant or award | +6,405 | — | 17,798 | Form 4 |
| 10 June 2026 | Yang Michael J. | Director | Grant or award | +6,405 | — | 19,798 | Form 4 |
| 10 June 2026 | Young Alethia | Director | Grant or award | +6,405 | — | 17,798 | Form 4 |
| 10 June 2026 | Christie Christopher | Director | Grant or award | +6,405 | — | 23,059 | Form 4 |
| 10 June 2026 | Hirawat Samit | Director | Grant or award | +6,405 | — | 6,405 | Form 4 |
| 4 June 2026 | Williams Kristen | Chief Administrative Officer | Open-market sale, 10b5-1 plan | −10,259 | $22.27 | 167,062 | Form 4 |
| 3 June 2026 | Williams Kristen | Chief Administrative Officer | Shares withheld for tax, 10b5-1 plan | −8,528 | $22.32 | 177,321 | Form 4 |
| 3 June 2026 | Slonin Jonathan | Chief Medical Officer | Shares withheld for tax | −4,728 | $22.32 | 218,912 | Form 4 |
| 3 June 2026 | Riker Lauren | Senior Vice President, Finance | Shares withheld for tax | −3,187 | $22.32 | 68,399 | Form 4 |
| 23 April 2026 | Cross Shawn | Chief Financial Officer | Option exercise, 10b5-1 plan | +12,941 | $16.45 | 118,282 | Form 4 |
| 23 April 2026 | Cross Shawn | Chief Financial Officer | Open-market sale, 10b5-1 plan | −12,941 | $25.16 | 105,341 | Form 4 |
| 22 April 2026 | Cross Shawn | Chief Financial Officer | Option exercise, 10b5-1 plan | +1,500 | $16.45 | 106,841 | Form 4 |
| 22 April 2026 | Cross Shawn | Chief Financial Officer | Open-market sale, 10b5-1 plan | −1,500 | $25.01 | 105,341 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Pacira Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.